Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Earnings Call Summary | Anika Therapeutics(ANIK.US) Q2 2024 Earnings Conference
Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Anika Therapeutics Analyst Ratings
Buy Rating Affirmed for Anika Therapeutics Amid Solid Financials and Strong Market Outlook
Anika Therapeutics, Inc. (ANIK): Are Hedge Funds Bullish on This Caligan Partners-Approved Stock?
Anika Therapeutics | 10-Q: Q2 2024 Earnings Report
Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate
Express News | Anika Therapeutics Inc -Expects 2024 Adjusted Ebitda to Be Towards the Lower End of the Previously Provided Range of $25 to $30 Million
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q2 EPS $0.17, Vs. Street Est of $0.20
Anika Therapeutics Non-GAAP EPS of $0.17 Misses by $0.03, Revenue of $41.9M Beats by $1.13M
Express News | Anika Therapeutics Q2 Income From Operations USD 161 Thousand
Express News | Anika Therapeutics Q2 Revenue USD 41.921 Million
Express News | Anika Therapeutics Q2 Gross Profit USD 27.365 Million
Express News | Anika Therapeutics Q2 Pretax Profit USD 756 Thousand
Express News | Anika Therapeutics Q2 Net Income USD -88 Thousand
Express News | Anika Reports Second Quarter 2024 Financial Results
Anika Therapeutics 2Q Loss/Shr 1c >ANIK
Here Is the Next Potential Market Catalyst